20 Humanities Postdoctoral positions at University of Maryland, Baltimore in United-States
-
-Seq, ChIP-Seq, ATAC-Seq, and more) to the bulk and single-cell samples from patient samples or their pre-clinical models (human and animal cell cultures, primary culture and patient-derived xenografts
-
scientific research involving human cell lines, mouse models, and clinical samples. Interested candidates should email CV and contact information for three references to Valeria R. Mas, MS, PhD, FAST Professor
-
including but not limited to immune cell culture assays, flow cytometry, Western blotting, Q-PCR, library creation and RNA and DNA sequencing Experience working with human samples is preferred Strong writing
-
infection in humans with the long-term goal of accelerating the development of novel vaccines. Studies will include exploration of the mechanisms operative in the generation of systemic and mucosal immunity
-
of Maryland-Baltimore as of June 1, 2018. MD, PhD or MD/PhD scientist is sought to join a laboratory at the forefront of academic drug discovery, cardiovascular biology and human induced pluripotent stem
-
of Cardiology at the University of Maryland-Baltimore immediately. MD, PhD or MD/PhD scientist is sought to join a laboratory at the forefront of academic drug discovery, cardiovascular biology and human induced
-
using Cre-Lox and gene therapy approaches to editing of MP in vivo. The gene therapy approaches are in pre-clinical development as novel therapies for humans with hypertension and heart failure
-
approaches. In addition, since aberrant activities of many of developmental pathways are thought to play a major role in pathogenesis of variety of human diseases, such as cancer, metabolic and cardiovascular
-
using Cre-Lox and AAV-Crispr/Cas9 editing of MP in vivo. The AAV-Crispr/Cas9 approach of editing is in pre-clinical development as a novel therapy for humans with hypertension and heart failure
-
using Cre-Lox and AAV-Crispr/Cas9 editing of MP in vivo. The AAV-Crispr/Cas9 approach of editing is in pre-clinical development as a novel therapy for humans with hypertension and heart failure